Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Factors Influencing Choice of Second-Generation BTKi Monotherapy
Specialists discuss factors influencing the choices of second-generation BTK monotherapy.
EP: 1.Recent Trends and Innovations in the Management of CLL
EP: 2.CLL Treatment Landscape: Overview of BTK Inhibitors
EP: 3.Evaluating Value of BTK Inhibitors in CLL Treatment
Now Viewing
EP: 4.Factors Influencing Choice of Second-Generation BTKi Monotherapy
EP: 5.Empowering Patients: Key Considerations for BTK Inhibitor Adherence
EP: 6.Optimizing Therapy Sequencing in CLL
EP: 7.Leveraging MAICs for Decision-Making in CLL BTK Inhibitor Selection
EP: 8.Decision-Making in CLL: The Role of Real-World Evidence
EP: 9.Combination Regimens with BTK Inhibitors: New Frontiers in CLL Treatment
EP: 10.Financial Challenges of BTK Inhibitor Therapy in CLL: Impact on Access and Utilization
EP: 11.Navigating Access Challenges in CLL Treatment: Strategies for Overcoming Barriers
EP: 12.The Inflation Reduction Act: Implications for Patient Access in CL
EP: 13.Patient Access Advocacy for BTK Inhibitors
EP: 14.Future Directions of BTK Inhibitors in Leukemia and Lymphoma
Video content above is prompted by the following question(s):
- When considering monotherapy with second-generation BTKi, what factors do you consider when choosing between available agents?
Related Videos
Related Content
Evolving Treatment Paradigms for Hematologic Malignancies in Community Oncology Settings
January 11th 2026Article
In an interview during ASH 2025, Ontada's Ira Zackon, MD explores the role of BTK inhibitors in chronic lymphocytic leukemia treatment, highlighting real-world challenges and emerging therapy strategies.
Read More
